|
OTCMarketbulls.com Reports Hot Market Movers For January 20, 2010 - Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) +45.69%, Cree, Inc. (NASDAQ: CREE) +16.01%, Rambus (NASDAQ: RMBS) +14.25%, CAVU Resources Inc. (OTC: CAVR) +9.37%
(M2 PressWIRE Via Acquire Media NewsEdge) As www.otcmarketbulls.com gains worldwide recognition we are rapidly becoming the MOST influential investing community available and we feel it is our obligation to show our appreciation by offering an all cash $20,000 giveaway!
OTCMarketBulls is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring value to shareholders. Some of our past picks had soared as much as 4600%. To view some of our profiled stocks, please visit our website at http://www.otcmarketbulls.com/OTCMBlandingpage.php.
____________________________
LXRX LATEST NEWS
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients - Significant Improvements in Glycemic Control - Significant Reduction in HbA1c within Four Weeks - Favorable Safety, Cardiovascular and Metabolic Profile Observed THE WOODLANDS, Texas, Jan. 20 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load. LX4211, dosed as a single agent, provided improvements in glycemic control, demonstrating statistically significant benefits in the primary and multiple secondary efficacy endpoints.
"Results from this important first trial of LX4211 in diabetic patients exceeded our expectations," said Dr. Philip M. Brown, senior vice president of clinical development at Lexicon. "Rapid improvement in multiple parameters of diabetes, meaningful weight loss, a favorable safety profile and the fact that LX4211-treated patients exhibited improvements in clinically-important metabolic and cardiovascular parameters within four weeks on a single agent is remarkable."
The recently completed study was a four-week, randomized, double-blind, placebo-controlled study in 36 patients with type 2 diabetes. Patients were randomized to receive either placebo (n=12) or LX4211, 150 mg (n=12) or 300 mg (n=12), once daily for 28 days. Patients were sequestered, provided a controlled diet and monitored closely throughout the study period.
There was a marked decrease in fasting plasma glucose throughout the treatment period in both dose groups, with reductions at week four of 53.4 mg/dl and 65.9 mg/dl in the 150 mg and 300 mg dose groups, respectively, as compared to 15.1 mg/dl for placebo. These decreases in fasting plasma glucose relative to placebo were statistically significant for both LX4211 dose groups (p=0.001 and p<0.001, respectively). Notably, a substantial percentage (42%) of patients in the 300 mg dose group achieved fasting plasma glucose levels of <105 mg/dl at week four of dosing as compared to placebo (p=0.037).
Importantly, after only four weeks of dosing, average percent hemoglobin A1c (HbA1c), a measure of blood glucose levels over time, was significantly reduced by 1.15 in the 150 mg dose group (p=0.036) and by 1.25 in the 300 mg dose group (p=0.017), as compared to 0.49 in the placebo group. HbA1c levels were reduced to less than or equal to 7% for half the patients in both dose groups; baseline levels were 8.22%, 8.50% and 8.20% for the 150 mg, 300 mg, and placebo groups, respectively. Patients in both dose groups also exhibited significantly improved glucose tolerance in response to oral glucose tolerance testing as compared to patients receiving placebo (p<0.001 for both dose groups), as measured by area under the curve (AUC). Consistent with the mechanism of action of LX4211, there was also a significant, dose-dependent increase in 24-hour urinary glucose excretion throughout the study period relative to placebo in both dose groups (p<0.001 at all time points measured).
With respect to broader metabolic and cardiovascular safety parameters, patients in both dose groups showed weight reduction accompanied by decreased blood pressure and triglycerides relative to placebo. LX4211 demonstrated a favorable safety profile in the study with no dose-limiting toxicities. Adverse events were generally mild and equally distributed across all groups, including the placebo group.
"The magnitude and rapid response in glycemic control, combined with the triglyceride reduction, may distinguish LX4211 from other agents in this class," said Dr. Brian Zambrowicz, chief scientific officer of Lexicon. "We now believe that the action of LX4211 cannot be entirely explained by glucose excretion in the urine alone, but may also relate to secondary events that both further enhance glycemic control and provide the other metabolic improvements we have witnessed in this study."
In addition to LX4211, Lexicon has three additional drug candidates progressing through Phase 2 clinical trials: LX1032, a peripherally-available serotonin synthesis inhibitor for carcinoid syndrome; LX2931, an S1P lyase inhibitor for rheumatoid arthritis; and LX1031, a locally-acting serotonin synthesis inhibitor for irritable bowel syndrome, which recently completed a Phase 2a clinical trial with positive results.
"We believe the latest encouraging results with LX4211 demonstrate the potential for a therapeutic benefit for patients with type 2 diabetes," said Dr. Arthur T. Sands, president and CEO of Lexicon. "With positive results within the last few months from Phase 2 clinical trials of two candidates, we are proceeding with confidence that our drug discovery platform has produced investigational new drugs with great promise for patients."
For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.
About the LX4211 Mechanism of Action
LX4211 was developed at Lexicon as a potent inhibitor of the sodium glucose cotransporter 2 (SGLT2), a transporter responsible for the majority of glucose reabsorption by the kidneys. Lexicon found that mouse knockouts engineered to lack the SGLT2 gene are healthy and require less insulin to manage a glucose challenge. LX4211 may potentially treat diabetes by improving glycemic control as well as providing other metabolic benefits.
About Diabetes
Diabetes mellitus is a common metabolic disorder associated with abnormally high blood sugar levels. Diabetes is classified as either type 1, which is characterized by severely diminished insulin production, or type 2, which is characterized by moderately diminished insulin production in conjunction with insulin resistance (insensitivity of the tissues of the body to insulin). Insulin is a hormone that regulates blood glucose levels. Diabetes can seriously impair overall quality of life and may lead to multiple complications including heart disease, stroke, and kidney failure. According to the International Diabetes Federation, more than 245 million people have diabetes, with type 2 diabetes being the most prevalent.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
____________________________
CREE LATEST NEWS
Cree Brings the LED Lighting Revolution Home New Residential Fixture Demonstrated at 2010 International Builder's Show DURHAM, N.C.--(1/20/10)--Cree, Inc. (Nasdaq: CREE), a market leader in LED lighting, announces the demonstration of a new 6-inch LED downlight designed for the residential market. The Cree CR6 LED downlight is being shown this week at the 2010 International Builder's Show in Las Vegas.
"By delivering the beautiful warm light created by Cree TrueWhite technology in an affordable, energy-efficient LED residential fixture, we're providing consumers with an alternative to energy wasting incandescents and the poor color-rendering of compact fluorescent bulbs," said Neal Hunter, President of Cree LED Lighting. "There is no residential LED downlight on the market today that can come close to matching the value and performance of the CR6. This product builds on the success of the award-winning LR6, which has shipped more than 350,000 units to date."
The Cree CR6 LED takes the technology at the heart of the LR6 family and redesigns it to deliver maximum value for residential lighting. The CR6 downlight, planned for availability in mid-2010, is being designed to meet ENERGY STAR criteria and for an end user price of approximately $60.
As demonstrated in residential applications at the Builder's Show, Cree TrueWhite technology can deliver the warm light and beautiful color rendering that consumers should expect from energy-efficient lighting.
About Cree
Cree is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb through the use of energy-efficient, environmentally friendly LED lighting. Cree is a market-leading innovator of lighting-class LEDs, LED lighting, and semiconductor solutions for backlighting, wireless and power applications.
Cree's product families include LED fixtures and bulbs, blue and green LED chips, high-brightness LEDs, lighting-class power LEDs, power-switching devices and radio-frequency/wireless devices. Cree solutions are driving improvements in applications such as general illumination, electronic signs and signals, variable-speed motors, and wireless communications.
For additional product and company information, please refer to www.CreeLEDLighting.com. To learn more about the LED Lighting Revolution, please visit www.creeledrevolution.com.
___________________________
RMBS LATEST NEWS
Samsung and Rambus Sign Comprehensive Agreement
SEOUL, South Korea & LOS ALTOS, Calif.--(1/20/10)--Samsung Electronics and Rambus (NASDAQ:RMBS) announced today that they have reached agreement settling all claims between them and licensing Rambus' patent portfolio covering all Samsung semiconductor products including a perpetual fully paid-up license to certain current DRAM products. As part of the overall agreement, Samsung will invest $200M in Rambus stock. Other consideration to Rambus includes an initial payment of $200M and a quarterly payment of about $25M for the next five years.
In addition, Samsung and Rambus have signed a memorandum of understanding (MOU) relating to a new generation of memory technologies which brings together Samsung's leadership in memory technologies with Rambus' innovations in high performance memory interfaces. The two companies will initially focus on graphics and mobile memory solutions and will further review a potential collaboration on server and high-speed NAND Flash memories.
Both Samsung and Rambus said they are pleased to resolve their differences and move forward.
"We have a tremendous opportunity to renew a partnership which has created solutions that have benefited consumers worldwide," said Harold Hughes, President and CEO of Rambus. "Bringing together Samsung's market and technology leadership with our innovations for high-performance and high-efficiency memory architectures will make possible an exciting new generation of mobile, computing and consumer electronics products."
Rambus management will discuss this agreement during a special conference call today at 3:00 p.m. PT. The call will be webcast and can be accessed through the Rambus website. A replay will be available following the call on Rambus' Investor Relations website or for one week at the following numbers: (888) 203-1112 (domestic) or (719) 457-0820 (international) with ID# 4815324.
About Samsung
Samsung Electronics Co., Ltd. is a global leader in semiconductor, telecommunication, digital media and digital convergence technologies with 2008 consolidated sales of US$96 billion. Employing approximately 164,600 people in 179 offices across 61 countries, the company consists of seven independently operated business units: Visual Display, Mobile Communications, Telecommunication Systems, Digital Appliances, IT Solutions, Semiconductor and LCD. Recognized as one of the fastest growing global brands, Samsung Electronics is a leading producer of digital TVs, memory chips, mobile phones and TFT-LCDs. For more information, please visit www.samsung.com.
About Rambus
Rambus is one of the world's premier technology licensing companies. Founded in 1990, the Company specializes in the invention and design of architectures focused on enhancing the end user experience of computing, communications and consumer electronics applications. Rambus' patented innovations and breakthrough technologies in the area of high-speed memory architectures and complementary technologies have helped industry-leading chip and system companies bring superior products to market. Rambus' technology and renowned integration expertise solve some of the most complex chip and system-level interface challenges. Rambus licenses both its world-class patent portfolio as well as its family of leadership and industry-standard interface products. Headquartered in Los Altos, California, Rambus has regional offices in North Carolina, Ohio, India, Germany, Japan, and Taiwan. Additional information is available at www.rambus.com.
____________________________
CAVR LATEST NEWS
CAVU Resources, Inc. Announces Completion of Phase One of the Pauls Valley Redevelopment Plan TULSA, OK--(01/20/10) - CAVU Resources, Inc. (Pinksheets:CAVR) announced today the completion of Phase One of the redevelopment plan on the 140 acre Pauls Valley Project in Garvin County, Oklahoma.
The recently acquired FILO Quip Resources, LLC is the owner and operator of the project. FILO will be 100% owned by CAVU under the modified acquisition agreement closed in October. With recent engineering and on site assessment, the company reworked two producing wells with down-hole reservoirs and targeted two other wells that are scheduled to be reworked and completed in new formations.
The Chisolm B-2 was previously re-entered to the Bromide formation at about 3,000 feet then deepened to the Basal Oil Creek formation at about 3,800 feet. FILO has installed a high tech submersible pump with a planned wireless SCADA system allowing the wells to be monitored and controlled online. After analyzing the recent production data and recalibrating the well, its daily production has increased 20% to 30 barrels of oil per day ("BOPD").
The Nabors-1 was re-entered to a depth of 3,100 feet, with the production zone being the Bromide. The well has been perforated and is currently being acidized, with initial production estimates at 20 to 30 BOPD.
FILO has begun the permitting process to re-enter two additional wells on the lease and plans to deepen them to about 4,000 feet with the targeted Tulip Creek and the Basal Oil Creek formations. Based upon results of the two existing producers and other wells contiguous to the lease, FILO anticipates each of the wells could have an average initial production rate of between 30 and 40 BOPD.
To handle the expected produced salt water from each of the wells, FILO reworked the current disposal well and increased the size of the tubing along with replacing the existing steel disposal lines. A new Wheatley Tri-Plex injection pump has been installed, with capabilities of moving up to 3,000 barrels of produced water a day.
FILO has also engaged a Petroleum Engineer to design and start the permitting process for a 25,000-barrel a day commercial disposal well on the 140-acre site. This would give increased capacity to the current and targeted surrounding wells and allow third party disposal at prices up to $.50 a barrel.
"This project is rapidly becoming a showcase for the low risk opportunities that requires less capital, but yet still offers excellent potential returns on CAVU's investment," said William C. Robinson, President of CAVU Resources, Inc.
About CAVU Resources, Inc.
During World War II, Navy fighter pilots would look up at the sky and if it was a 'CAVU' day then it meant ceiling and visibility unlimited. The founders of CAVU Resources chose the name CAVU because they believe that the Company will be the embodiment of its name. CAVU was formed with the goal of becoming a recognized regional player in the independent oil and natural gas industry by growing the company's oil and natural gas reserves. CAVU is a natural resource company engaged in the acquisition, exploration and development of oil and natural gas properties. The Company operates in the upstream segment of the oil and gas industry with planned activities including the drilling, completion and operation of oil and gas wells in Oklahoma, Kansas, Colorado and Texas. The Company also owns two pipelines in its area of operations, which will be used for gathering its gas and oil and the gas and oil production of other producers. The Company has acquired leases and is currently exploring additional opportunities in oil, gas and helium leases. The company has acquired significant oil and gas equipment including rigs, trucks and completion equipment. CAVU's 100% owned subsidiaries, CAVU Energy Services, LLC provides contract drilling, fracture stimulation and directional drilling services to oil, natural gas exploration and production companies. EnviroTek Fuel Systems, Inc., providing natural gas delivery and marketing thru its own pipelines, CAVU Operating Company, LLC managing the company's properties and targeted leases in Oklahoma, Texas, Colorado and Montana. CAVU plans to expand operations not only in the traditional Oil and Gas business, but also to invest in Geo-Thermal, Wind, Solar and security, taking advantage of the changing environment and in the world's need for new, green and innovative resources. More information is available at the company's website at http://www.cavu-resources.com.
____________________________
OTCMarketbulls.com is an online financial destination where money managers, analysts, and individual investors can converge to discover new and exciting investment news, opportunities, and ideas. OTCMarketBulls.com is focused on finding emerging growth companies that do not necessarily have widespread analyst coverage on Wall Street. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTCMarketBulls.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
For full disclaimer/disclosure: http://www.otcmarketbulls.com/disclaimer.php
Visit Us On Twitter and Facebook: http://twitter.com/otcmarketbulls http://www.facebook.com/otcmarketbulls
SIGN UP FOR OUR FREE NEWSLETTER AND FREE EMAIL ALERTS!! http://www.otcmarketbulls.com/OTCMBlandingpage.php
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ Back To TMCnet.com's Homepage ]
|
TMCnet LOGIN
Webinars
